Roivant Sciences Ltd. (ROIV) Financial Statements (2026 and earlier)

Company Profile

Business Address 7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
State of Incorp.
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
MRQ
3/31/2025
3/31/2024
3/31/2023
3/31/2022
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4,886,8916,535,7061,676,8132,060,400
Cash and cash equivalent2,715,4116,535,7061,676,8132,060,400
Short-term investments2,171,480   
Restricted cash and investments    3,903
Receivables  53,54530,379 
Inventory, net of allowances, customer advances and progress billings  35,2512,761 
Inventory  35,2512,761 
Other current assets113,173196,122121,77482,220
Other undisclosed current assets  (88,796)(33,140) 
Total current assets:5,000,0646,731,8281,798,5872,146,523
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization   5,885 
Operating lease, right-of-use asset89,02146,89253,25161,044
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization12,05619,05839,08625,905
Intangible asset, including goodwill, after accumulated amortization  137,842144,881 
Intangible asset, excluding goodwill, after accumulated amortization  137,842144,881 
Restricted cash and investments7,8929,37710,2919,731
Other noncurrent assets32,86039,10949,48216,092
Other undisclosed noncurrent assets295,047238,376288,141325,834
Total noncurrent assets:436,876490,654591,017438,606
TOTAL ASSETS:5,436,9407,222,4822,389,6042,585,129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities137,985228,811204,959162,114
Accounts payable23,69153,22537,83034,583
Accrued liabilities114,294175,586167,129127,531
Deferred revenue    10,147
Debt  12,00042,810 
Other liabilities1,58416,05415,076708
Other undisclosed current liabilities9,8429,8939,60311,398
Total current liabilities:149,411266,758272,448184,367
Noncurrent Liabilities
Long-term debt and lease obligation   3,574272,493
Long-term debt, excluding current maturities    210,025
Finance lease, liability   3,574 
Liabilities, other than long-term debt90,35050,86770,50821,923
Deferred revenue    13,740
Other liabilities223,60217,0328,183
Operating lease, liability90,32847,26553,47662,468
Other undisclosed noncurrent liabilities 9,981456,328435,48744,912
Total noncurrent liabilities:100,331507,195509,569339,328
Total liabilities:249,742773,953782,017523,695
Temporary equity, including noncontrolling interest    22,491
Equity
Equity, attributable to parent4,687,6055,968,5811,157,7661,656,944
Additional paid in capital4,562,1075,396,4924,933,1374,421,614
Accumulated other comprehensive income (loss)9,438(4,083)(2,617)(946)
Retained earnings (accumulated deficit)116,060576,172(3,772,754)(2,763,724)
Equity, attributable to noncontrolling interest499,593479,948449,821381,999
Total equity:5,187,1986,448,5291,607,5872,038,943
TOTAL LIABILITIES AND EQUITY:5,436,9407,222,4822,389,6042,585,129

Income Statement (P&L) ($ in thousands)

12/31/2025
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Revenues29,053124,79561,28055,286
Gross profit:29,053124,79561,28055,286
Operating expenses(1,142,734)(1,231,189)(1,236,598)(1,406,928)
Other undisclosed operating income 110,3875,348,410  
Operating income (loss):(1,003,294)4,242,016(1,175,318)(1,351,642)
Nonoperating income (expense)47,573(21,290)24,269(90,726)
Investment income, nonoperating58,294(15,201)8,461(87,291)
Other nonoperating income (expense)(10,721)(6,089)15,808(3,435)
Interest and debt expense (8,848)(34,778)(27,968)(7,041)
Other undisclosed income from continuing operations before equity method investments, income taxes    525,662
Income (loss) from continuing operations before equity method investments, income taxes:(964,569)4,185,948(1,179,017)(923,747)
Other undisclosed income (loss) from continuing operations before income taxes282,97967,482(45,817) 
Income (loss) from continuing operations before income taxes:(681,590)4,253,430(1,224,834)(923,747)
Income tax expense(48,174)(22,224)(5,190)(369)
Income (loss) from continuing operations:(729,764)4,231,206(1,230,024)(924,116)
Loss before gain (loss) on sale of properties:(924,116)
Income from discontinued operations 373,030 114,561 
Net income (loss):(356,734)4,231,206(1,115,463)(924,116)
Net income attributable to noncontrolling interest184,753117,720106,43378,854
Net income (loss) available to common stockholders, diluted:(171,981)4,348,926(1,009,030)(845,262)

Comprehensive Income ($ in thousands)

12/31/2025
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Net income (loss):(356,734)4,231,206(1,115,463)(924,116)
Other comprehensive income (loss)13,459(936)(1,490)(2,271)
Comprehensive income (loss):(343,275)4,230,270(1,116,953)(926,387)
Comprehensive income, net of tax, attributable to noncontrolling interest184,815117,190106,25278,734
Comprehensive income (loss), net of tax, attributable to parent:(158,460)4,347,460(1,010,701)(847,653)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: